PSA is thus under the androgenic control and currently the most commonly used biomarker for the diagnosis and prognosis of prostate cancer, by measuring the level/amount of serum PSA (secreted from prostate epithelial cells) [5]. This evidence concerns the gene KLK3 and Familial prostate cancer.